Association Between Pococyturia and Pre-eclampsia Severity
- Conditions
- Pre-Eclampsia
- Interventions
- Other: Dosage of urinary podocyturia
- Registration Number
- NCT03316391
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
Pre-eclampsia is an hypertensive disorder appearing during pregnancy, inducing serious maternal, fetal and neonatal mortality and morbidity. Twenty four hours proteinuria is a key element to define pre-eclampsia severity but is delaying the result by 24 hours and constraining for the patient. A simple and rapid indicator for severe preeclampsia would help clinicians to make appropriate decision in patient management. We hypothesized that urinary podocyturia is correlated to preeclampsia severity. This is a prospective, non-interventional, monocentric study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 30
- women aged 18 years or more
- single pregnancy
- admission for pre-eclampsia
- patient receiving information and non-opposition to participate
- multiple pregnancy
- in utero fetal demise excepted if associated with pre-eclampsia
- antecedent of nephropathy
- fetal malformation, chromosomal anomalies
- inability to understand information provided
- prisoner or under administrative supervision
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Pre-eclampsia Dosage of urinary podocyturia Patients in hospital for pre-eclampsia at the Hopital Femme-Mère-Enfant
- Primary Outcome Measures
Name Time Method Severity of pre-eclampsia at childbirth (maximum 10 months) Severe preeclampsia is defined by preeclampsia with at least one of the following criteria :
* severe hypertension (PAS ≥ 160 mmHg et/ou PAD ≥ 110 mmHg)
* Renal impairment with: oliguria \<500 ml / 24h or creatinine\> 135 μmol / L or proteinuria\> 5 g/d
* acute lung edema or persistent epigastric bar or HELLP syndrome
* eclampsia or rebellious neurological disorders (visual disturbances, polykinetic ROT, headache),
* thrombocytopenia \<100 G / L
* Retro Placental Hematoma (HRP) or fetal repercussion.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Service de gynécologie-obstétrique
🇫🇷Pierre-Bénite, Rhône, France
Department of obstetrics, Femme Mère Enfant Hospital, Lyon, France
🇫🇷Bron, France